Goldman Sachs Group Inc Clovis Oncology, Inc. Transaction History

Goldman Sachs Group Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 May 14, 2024	SELL	$1.05 - $2.85 $106,802 - $289,893	-101,717 Reduced 42.1%	139,904 $166,000
Q3 2022 Nov 10, 2022	SELL	$1.05 - $2.85 $106,802 - $289,893	-101,717 Reduced 42.1%	139,904 $166,000
Q2 2022 May 14, 2024	BUY	$0.63 - $2.96 $152,221 - $715,198	241,621 New	241,621 $435,000
Q2 2022 Aug 15, 2022	SELL	$0.63 - $2.96 $34,902 - $163,984	-55,400 Reduced 18.65%	241,621 $435,000
Q1 2022 May 16, 2022	SELL	$1.43 - $3.14 $282,333 - $619,949	-197,436 Reduced 39.93%	297,021 $600,000
Q4 2021 Feb 14, 2022	SELL	$2.7 - $4.76 $25,096 - $44,244	-9,295 Reduced 1.85%	494,457 $1.34 Million
Q3 2021 Nov 10, 2021	BUY	$4.06 - $5.8 $2.05 Million - $2.92 Million	503,752 New	503,752 $2.25 Million

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.